Octoplus« Terug naar discussie overzicht

1. flosz 26 oktober 2011 08:35

   auteur info

   •    flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   •    Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Even de volledige berichtgeving in een apart draadje.
   
   NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO
   OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA
   OCTOPLUS LAUNCHES EQUITY OFFERING WITH AIMED PROCEEDS
   OF €4 MILLION
   
   Leiden, the Netherlands, 25 October 2011 – OctoPlus N.V. (“OctoPlus” or the “Company”)
   (Euronext: OCTO), announces today that it launches an offering of ordinary shares with an aim of raising gross proceeds of €4 million (the “Offering”).
   The Offering shall be structured as a private placement. The offer price of the ordinary shares offered is €0.50 per share (the “Offer Price”).
   Petercam will act as sole lead manager and placement agent in relation to the Offering. The Offering shall be launched immediately following the release of this announcement and is expected to close on Wednesday 26 October 2011. Settlement of the Offering is expected to take place on Monday 31 October 2011.
   
   With regard to the Offering:
   OctoPlus swaps an amount of new shares that is equal to the number of shares offered in the Offering with three major shareholders in exchange for an equal number of existing
   ordinary shares of OctoPlus currently held by these shareholders.
   
   The existing ordinary shares, which are delivered to OctoPlus, will be placed by OctoPlus in a non-pre-emptive placement with qualified investors in the Netherlands and elsewhere in the framework of the Offering.
   
   A number of the Company’s existing shareholders, including the Company's CEO, Mr. Jan Hendrik Egberts, and certain new investors have committed themselves to subscribe for shares in the Offering for a substantial part of the amount that OctoPlus aims to raise, subject to €4 million in gross proceeds being raised.
   
   The new ordinary shares will rank pari passu in all respects with OctoPlus’ existing issued ordinary shares and in order to ensure that the new ordinary shares are marketable on the stock exchange of NYSE Euronext in Amsterdam OctoPlus will procure to have the new ordinary shares listed and admitted to trading on NYSE Euronext in Amsterdam on or before the date that is 90 days after the settlement of the Offering on the basis of a prospectus to be prepared by OctoPlus and be approved by the Dutch Authority for the Financial Markets (AFM) and in accordance with the rules and regulations of NYSE Euronext in Amsterdam.
   
   www.octoplus.nl/index.cfm/octoplus/in...
2. flosz 26 oktober 2011 09:24

   auteur info

   •    flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   •    Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Oct. 26, 2011, 3:15 a.m. EDT
   OctoPlus successfully completes equity offering with gross proceeds of EUR 4 million
   
   Leiden, Netherlands, Oct 26, 2011 (Thomson Reuters ONE via COMTEX) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTOOR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA
   
   Further to its press release of 25 October 2011, OctoPlus N.V. ("OctoPlus" or the "Company") , announces today that it has successfully completed an equity raising with EUR 4 million gross proceeds through a private placement of 8 million shares at an offer price of EUR 0.50 per share with new and existing investors.
   In the context of the Offering 8 million new ordinary shares with a nominal value of EUR 0.12 will be issued and following such issue, the Company will have 44.778.974 shares in issue. The Company's CEO Mr. Jan Hendrik Egberts purchased 300.000 shares in the Offering.
   Petercam acted as sole lead manager and placement agent in relation to the Offering. Settlement of the Offering is expected to take place on Monday 31 October 2011.
   
   OctoPlus intends to use the proceeds of the private placement for working capital purposes and to retain upside by co-investing along with clients in selected high-value projects in the area of specialty generics.
   Jan Egberts, CEO of OctoPlus, says: "We are very happy with this additional support from both existing and new investors as well as the continued support from our founder, Joost Holthuis. The proceeds of this financing will strengthen our balance sheet and enable us to act on investment opportunities in the area of specialty generics".
   www.marketwatch.com/story/octoplus-su...
   
3. flosz 18 november 2011 21:20

   auteur info

   •    flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   •    Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   Notifiable Share Interest in OctoPlus N.V.
   
   GlaxoSmithKline plc ("GSK") announces that following a private placement offering made by OctoPlus N.V. ("OctoPlus"), a pharmaceuticals product and drug delivery company located in the Netherlands and whose shares are traded on Euronext Amsterdam, on 26 October 2011, GSK's interest in Octoplus has decreased.
   
   GSK's interest, which is held by S.R. One, Limited,a wholly owned US-registered subsidiary of GSK ("S.R.One"), now comprises 4,345,062 ordinary shares or 9.7% of OctoPlus. The calculation is based on a total of 44,778,974 shares outstanding in OctoPlus. This decreased interest became disclosable under the rules of the Dutch Financial Supervision Act upon falling below 10% of the issued share capital of OctoPlus, and a notification regarding this decreased holding is due to be made to the Netherlands Authority for the Financial Markets ("AFM") on 18 November 2011.
   
   Victoria Whyte
   Company Secretary
   
   18 November 2011
   
   tinyurl.com/7c34zh3
   
4. [verwijderd] 19 november 2011 08:26

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   flosz schreef:

   Notifiable Share Interest in OctoPlus N.V.
   
   GlaxoSmithKline plc ("GSK") announces that following a private placement offering made by OctoPlus N.V. ("OctoPlus"), a pharmaceuticals product and drug delivery company located in the Netherlands and whose shares are traded on Euronext Amsterdam, on 26 October 2011, GSK's interest in Octoplus has decreased.
   
   GSK's interest, which is held by S.R. One, Limited,a wholly owned US-registered subsidiary of GSK ("S.R.One"), now comprises 4,345,062 ordinary shares or 9.7% of OctoPlus. The calculation is based on a total of 44,778,974 shares outstanding in OctoPlus. This decreased interest became disclosable under the rules of the Dutch Financial Supervision Act upon falling below 10% of the issued share capital of OctoPlus, and a notification regarding this decreased holding is due to be made to the Netherlands Authority for the Financial Markets ("AFM") on 18 November 2011.
   
   Victoria Whyte
   Company Secretary
   
   18 November 2011
   
   tinyurl.com/7c34zh3
   
   

   Hebben niet meegedaan met de emissie.
5. peebee 19 november 2011 10:32

   auteur info

   •    peebee

     Lid sinds: 16 nov 2009

     Laatste bezoek: 14 aug 2024

   •    Aanbevelingen

     Ontvangen: 115

     Gegeven: 41

   •    Aantal posts: 1.723

   quote:

   EdNet schreef:

   [...]
   
   Hebben niet meegedaan met de emissie.
   

   klopt, blijven zo weinig bedrijven/personen over die wel mee hebben gedaan.